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Eric K. Peden, MD, and Alan B. Lumsden, MD, Houston, Tex
Background: Aggressive endoluminal therapy for superficial femoral artery (SFA) occlusive disease is commonplace, but
the outcomes of current management of recurrent disease have not been well defined. This study examined the outcomes
of endoluminal and open interventions for recurrent SFA disease.
Methods: A database of patients undergoing endovascular treatment of the SFA between 1986 and 2008 was retrospec-
tively queried, and those with recurrent disease were selected. Outcomes were determined by Kaplan-Meier survival
analyses, and the Cox proportional hazard model was used for time-dependent variables.
Results: Symptomatic SFA disease resulted in endovascular treatment in 735 limbs in 631 patients (64%male; average age,
67 years). The restenosis rate was 16%  3% at 5 years. Restenosis developed in 222 patients, of whom 58 remained
asymptomatic and 164 underwent repeat intervention comprising percutaneous transluminal angioplasty (PTA) in 59%
and bypass in 41%. Bypass was used for critical ischemia (rest pain/tissue loss: 52% repeat PTA vs 75% bypass) and inmore
extensive recurrent disease (TransAtlantic Inter-Society Consensus [TASC] II C/D lesions: 42% repeat PTA vs 67%
bypass). Primary and repeat PTA had mean  standard error of the mean equivalent cumulative patency (73%  9% vs
73% 3% at 5 years) and duration of symptom relief (66% 3% vs 63% 6%). Bypass had significantly superior outcomes
for patency (93%  8%) and symptom relief (81%  8%), but morbidity was 28% vs 16% for PTA. Critical ischemia,
TASC-II lesion (C/D), and one-vessel tibial runoff were significant predictors of failure in the repeat PTA group.
Conclusions:Reintervention is required in a minority of patients selected for SFA angioplasty. Bypass for recurrent disease
is used more commonly for extensive disease and is associated with superior long-term outcomes but higher mortality.
Bypass rather than repeat PTA may be the better strategy for progressive, complex recurrent disease. ( J Vasc Surg 2010;
52:331-9.)Endoluminal therapy for superficial femoral artery
(SFA) occlusive disease is now commonplace, and the
techniques have diffused throughout the interventional
and surgical community.1,2 The technology and technical
skills in practice have permitted more andmore challenging
lesions to be tackled,3,4 and this progress can be charted in
the changes made in the recommendations for SFA occlu-
sive disease between the Trans-Atlantic Inter-Society Con-
sensus (TASC) I5 and TASC-II documents.6 Multiple re-
ports have demonstrated that presenting symptoms,
diabetes, and runoff will affect the anatomic and functional
outcomes after SFA intervention.7-11 Furthermore, an un-
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mise subsequent surgery and long-term outcomes.12,13
With the increasing volume of SFA interventions has
come an increase in repeat interventions for recurrent dis-
ease. Early articles on this subject suggested that these
interventions did not fare as well as the primary interven-
tion.13,14 Since these reports were published, additional
technologies have been made available and different ap-
proaches have been taken for reinterventions on recurrent
SFA lesions.3,4 The aim of this study was to examine the
outcomes of endoluminal and open interventions for recur-
rent SFA disease.
METHODS
Study design. A database of patients undergoing en-
dovascular treatment of SFA between 1986 and 2008 was
retrospectively queried, and those with recurrent disease
were selected. Three groups were developed: primary endo,
those undergoing primary endovascular SFA intervention;
repeat endo, those undergoing repeat endovascular SFA
intervention for recurrent disease; and bypass, those who
underwent bypass surgery for recurrent disease after a pri-
mary SFA intervention. Methodology, definitions of co-
morbidities and outcomes are shown in the Appendix (on-
line only). Data utilization fell under the category of
secondary use of preexisting data as defined by the Institu-
tional Review Board and Health Insurance Portability and
Accountability Act.
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formed on an intention-to-treat basis. Measured values are
reported as percentages or means  standard deviation.
Patency and limb salvage rates were calculated using
Kaplan-Meier analysis and reported using current Society
for Vascular Surgery (SVS) criteria.15 Kaplan-Meier analy-
ses are reported with standard errors. Cox proportional
hazard analyses and univariate and multivariate analyses
were performed to identify factors associated with out-
comes. Analyses were performed using JMP 7.0 software
(SAS Institute, Cary, NC).
RESULTS
Patient population. A total of 735 limbs in 631 pa-
tients (64% male; average age, 67 years) underwent endo-
vascular treatment for symptomatic SFA disease. In the
primary endo group (Table I), 61% of these interventions
were for lifestyle-limiting claudication. The restenosis rate
was 16%  3% at 5 years. By Cox proportional hazards
analysis, the development of restenosis was associated with
the presence of metabolic syndrome (relative risk [RR],
1.33; P  .004), hemodialysis (RR, 1.72; P  .003),
critical limb ischemia (RR, 1.28; P  .001), TASC C/D
lesions (RR, 3.86; P .001), poor tibial runoff (RR, 1.24;
P  .001), and poor clinical response to intervention,
defined as lack of resolution of symptoms or 1-point rise
in SVS/Rutherford classification (RR, 2.23; P  .03).
Restenosis developed in 222 patients, of whom 58
remained asymptomatic, and 164 underwent repeat inter-
ventions consisting of 59% percutaneous (repeat endo) and
41% bypass procedures (Table I). Age and gender were
equivalent in the repeat endo and bypass groups. Smoking
history was more prevalent in both endovascular groups,
Table I. Characteristics of patients
Demographics Primary endo Repeat endo Bypass
P
value
Limbs treated, No. 735 96 68 . . .
Male, % 66 65 63 .87
Age, mean  SD, y 67  12 67  13 66  12 .81
Symptoms, %
Claudication 61 48 25 .02
Rest pain 16 19 28
Tissue loss 23 33 47
Comorbidities
Smoking history 78 85 67 .023
Current smoker 18 11 24 .12
CAD 47 65 82 .001
Hypertension 89 93 95 .13
Diabetes 51 58 56 .34
Hyperlipidemia 65 66 71 .64
Metabolic syndrome 57 61 74 .023
Cerebrovascular 13 11 15 .83
CKD 23 20 20 .88
Hypothyroidism 11 11 9 .84
Hypercoagulability 6 8 4 .55
CAD, Coronary artery disease; CKD, chronic kidney disease; SD, standard
deviation.and current smoking was more prevalent in the bypassgroup than in the endo groups (Table I). The bypass group
had a higher prevalence of coronary artery disease and
metabolic syndrome than either endo group (Table I). The
three groups had an equal prevalence of hypertension,
hyperlipidemia, diabetes, and chronic renal disease (Table
I). Approximately 60% of patients in each group were
taking statins. Equal percentages of patients had insulin-
dependent and non-insulin-dependent diabetes, and an
equal number required hemodialysis.
Presentation of recurrent disease was dissimilar to the
initial presenting symptoms in the primary endo group.
The repeat endo group had more critical ischemia than the
primary endo group, whereas the bypass group had more
tissue loss (Table I). When each patient cohort was exam-
ined, the distribution of symptoms from initial presentation
to repeat presentation was similar in the group treated with
repeat endovascular intervention; however, there was a
marked progression of presentation of disease in those who
required bypass (Fig 1, A).
Anatomy. Patients presenting with recurrent disease
and undergoing repeat endo had a similar distribution of
TASC-II lesions as did the primary endo group, whereas
those undergoing bypass had a greater number of TASC-II
C and D lesions (Table II). Repeat endo was used for the
entire range of restenosis categories (1-4), with more than
half being occlusive. Bypass surgery was nearly exclusively
used for III and IV restenosis categories (Table II).
When traditional runoff scores and a modified SVS
runoff score were used to grade the runoff, there was no
difference in the group averages among primary endo,
repeat endo, and bypass (Table II). When each patient
cohort was examined, the distribution of TASC-II lesions
at the initial presentation and the repeat presentation was
similar in the group treated with repeat endovascular inter-
vention, whereas lesions were more advanced and had
progressed in those undergoing bypass (Fig 1, B). A similar
comparison undertaken for runoff showed that runoff was
worse in the patients who underwent repeat endovascular
intervention compared with the initial runoff score but had
markedly deteriorated in those who required bypass for
recurrent disease (Fig 1, C).
Immediate outcomes. The technical failure rates were
3% for primary endo and repeat endo and 0.5% for bypass.
Treatment modality did not influence outcome in the
repeat endo group. However, 50% of the lesions in the
repeat endo group required recannulization compared with
the primary endo group, and about 60% of the repeat endo
group underwent advanced techniques, including primary
stenting, atherectomy, and concomitant tibial angioplasty
to re-establish satisfactory anatomic results (Table III).
This was a switch from the primary endo group interven-
tions, where more iliac concomitant interventions were
performed, but would be consistent with the finding that
runoff had worsened in this group. In the bypass group,
there was an equal distribution of femoral above-knee to
popliteal, below-knee to popliteal, and tibial bypasses with
increasing use of vein as we moved down the leg. Endo-
scopic vein harvest was used in one-third of the cases.
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increased burden of coronary disease in the bypass group.
Morbidity was similar between the primary endo and the
repeat endo groups but was greater in the bypass group,
being mainly driven by an increase in local complications,
Fig 1. Difference in (A) symptom presentation, (B) TransAtlantic
Inter-Society Consensus (TASC) II lesion category, and (C) tibial
runoff of patients presenting with recurrent symptoms who under-
went repeat percutaneous transluminal angioplasty (PTA) or by-
pass.predominantly wound-related (Table IV).Hemodynamically, there was a marked increase in
ankle-brachial indexes (ABIs) across all three groups, with
70% of patients having a rise in their ABI of0.15. After
primary endo intervention, 82% of patients were considered
to have improved or resolved symptoms. This dropped to
54% in the repeat endo group, with a significantly greater
number of patients showing no change in symptoms. In the
bypass group, 95% were considered to have improved or
resolved symptoms.
Short-term clinical efficacy, which was defined as ab-
sence of recurrent symptoms for 1 year, patency of the
intervention until wound healing, limb salvage for 1 year,
maintenance of ambulation for 1 year, and survival for 1
Table II. Lesion characteristics
Characteristic
Primary
endo
Repeat
endo Bypass
P
value
TASC-II category, %
A/B 62 58 33 .001
C/D 38 42 67
Restenosis grade, %
1 14 0 .001
2 18 1
3 15 50
4 53 49
Runoff, mean  SD
Tibial vessels, No. 2.0  0.8 2.0  0.8 1.9  0.8 .61
Modified SVS runoff
score
6.2  4.2 5.9  4.3 6.5  4.1 .66
SD, Standard deviation; SVS, Society for Vascular Surgery; TASC,
TransAtlantic Inter-Society Consensus.
Table III. Procedures, complexity, hemodynamic
changes, and immediate symptom relief
A, Endovascular group
Procedure Primary endo Repeat endo P value
Intervention, %
Recannulization 26 55% .001
Angioplasty 69 41% .0003
Primary stenting 16 28%
Laser/directional
atherectomy
15 31%
Stent usage 25 31% .21
Adjunctive interventions, %
Aortoiliac intervention 10 6 .27
Tibial intervention 3 17 .001
Complexity score 1.2  0.5 1.3  0.5 .07
B, Bypass group
Bypass Veina Endoveinb
Fem AK pop, % 35 25 33
Fem BK pop, % 32 50 18
Fem tibial, % 32 85 40
Endovein, Endoscopic vein harvest; Fem AK pop, femoral to above knee
popliteal; Fem BK pop, femoral to below knee popliteal.
aP  .001; bP  .001.year, was 64%, 65%, and 67% in the primary endo, the
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There was no significant association with early failure (6
months) in the primary endo group and early failure in the
repeat endo group (P  .23). There was, however, a
significant association with early failure (6 months) in the
primary endo group and early failure in the bypass group
(P  .0002).
Long-term anatomic outcomes. There was no signif-
icant difference in the primary patency of the primary endo
and the repeat endo groups (Fig 2,A). The primary patency
of the bypass group was also equivalent to both endo
groups, with 5-year rates of 60%  3%, 67%  10%, and
69%  8%, respectively, in the primary endo, repeat endo
and bypass groups. Freedom from restenosis at 5 years was
76%  3%, 72%  9%, and 92%  8%, respectively, in the
primary endo, repeat endo, and bypass groups (Fig 2, B).
Assisted primary patency was higher in the bypass group,
showing a significant advantage over both endo groups
(Fig 2, C), with 5-year rates of 73%  3%, 74%  9%, and
84% 10%, respectively, in the primary endo, repeat endo,
and bypass groups.
A similar pattern was also seen for secondary patency
(Fig 2, D), with 5-year rates of 73%  3%, 73%  9%, and
92%  7%, respectively, in the primary endo, repeat endo,
and bypass groups. The patients in the repeat endo group
underwent up to a maximum of three additional interven-
tions tomaintain patency, and 36% of the repeat endo limbs
required one additional (second repeat) intervention, 20% a
third repeat intervention, and 3% a fourth repeat interven-
tion. Bypass was required in 14% of limbs in subsequent
follow-up after a first repeat endovascular intervention and
in 17% in subsequent follow-up after the second repeat
endovascular intervention.
Freedom from target lesion revascularization at 3 years
was equivalent in the primary endo and repeat endo groups
(57%  3% and 60%  10%) and superior in the bypass
group (69%  9%; Fig 2, E). The etiology of failure in the
Table IV. Outcomes
Outcome Primary endo
Mortality, % 1
Morbidity, % 16
Systemic, % 3
Local, % 13
Hemodynamic changes
ABI change, mean  SD 0.26  0.28
ABI increase 0.15, % 70
Immediate symptom relief
Resolved, % 49
Improved, % 33
No change, % 16
Deterioration, % 1%
Amputation
Toe and/or forefoot, % 2
Below knee, % 8
Above knee, % 4
ABI, Ankle-brachial index; SD, standard deviation.bypass group was early occlusion in 87% and conduit failure(multiple stenoses and negative remodeling) in the rest.
The etiology of failure in the endo group was a combina-
tion of recurrent recalcitrant stenosis (23%), occlusion
(50%), and symptomatic hemodynamic failure (27%).
There was no significant association with early failure (6
months) in the primary endo group and ultimate failure in
the repeat endo group (P  .45). Similarly, there was no
significant association with early failure (6 months) in the
primary endo group and ultimate failure in the bypass
group (P  .79).
By Cox proportional hazards analysis, the primary pa-
tency of repeat endo was negatively influenced by the
presence of metabolic syndrome (RR, 3.39; P .009) and
presenting symptoms (RR, 1.51; P  .03).The secondary
patency of repeat endo was negatively influenced by pre-
senting symptoms of critical ischemia (RR, 1.76; P  .01)
and TASC II C/D lesions (RR, 3.10; P  .046). Cox
proportional hazards analysis also showed the primary pa-
tency of bypass was negatively influenced by the presence of
a TASC II C/D lesion (RR, 2.78; P  .001), presenting
symptoms of critical ischemia (RR, 3.40; P  .04), and
poor runoff (RR, 3.65; P  .05). There was an inverse
linear trend with respect to presenting symptoms and out-
comes, with rest pain and tissue loss negatively influencing
the result (2 for trend  39.441; P  .0001). Tissue loss
was a poor prognosticator in those with critical ischemia
(P  .023).
Long-term functional outcomes. Patient survival
was 84%  3%, 96%  5%, and 91%  6% at 5 years and
65%  4%, 81%  10%, and 73%  10% at 10 years in the
primary endo, repeat endo, and bypass groups, respectively
(Fig 3, A). Survival was negatively influenced by the pres-
ence of congestive heart failure (RR, 1.48; P .0038) and
an estimated glomerular filtration rate60 mL/min/1.73
m2 (RR, 2.14; P  .0004). Runoff, a marker of advanced
atherosclerosis, was also associated with decreased survival
(RR, 1.81; P  .0001). The mortality rate was higher in
Repeat endo Bypass P value
2 0 .39
16 28 .04
4 3 .82
12 25 .02
0.32  0.23 0.40  0.24 .98
72 79 .25
.0001
28 60
28 35
41 3
3 1
.81
2 1
4 9
6 4patients presenting with critical ischemia (RR, 1.76; P 
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major amputation was also a negative influence on survival
(RR, 1.54; P  .0002).
Freedom from recurrent symptoms was superior in the
bypass group compared with the endo groups, and there
was no significant difference between the endo groups (Fig
Fig 2. Life-table analyses are shown for patients in the p
patency, (B) freedom from restenosis, (C) assisted prim
target lesion revascularization. Data are the mean stand
is presented in the Table. No error bars are shown if the S
is 10.3, B). The 5-year rate of freedom from recurrent symptomswas 67%  3%, 63%  9%, and 80%  7%, respectively, in
the primary endo, repeat endo, and bypass groups (P 
.03).
Limb salvage was similar between the primary endo,
repeat endo, and bypass groups (Fig 3, C). The limb-
salvage rate was 84%  2%, 79%  7%, and 69%  9% at 5
ry endo, repeat endo, and bypass groups for (A) primary
atency, (D) secondary patency, and (E) freedom from
rror of the mean (SEM), and the number of limbs at risk
s10%, and the data set terminates if the number at riskrima
ary p
ard e
EM iyears and 81% 3%, 79% 8%, and 70% 9% at 10 years,
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groups. Major amputations were required in 3%, 2%, and
8% of patients in the primary endo, repeat endo, and bypass
groups, respectively, presenting with claudication
(P  .23), and in 27%, 29%, and 48%, respectively, in
patients presenting with critical limb ischemia (P  .02).
Retained clinical success, defined as freedom from re-
current symptoms, maintenance of ambulation, and ab-
sence of a major amputation, was 61%  3%, 53%  10%,
and 44%  7% at 3 years in the primary endo, repeat endo,
and bypass groups, respectively (Fig 3, D). There was a
linear trend with lack of clinical improvement for the repeat
endo group (2  34.44; P  .0001) but not the bypass
group (2  3.228; P  .07), with those presenting with
tissue loss more likely than those with rest pain and both
more likely than those presenting with claudication. Non-
insulin-dependent diabetes mellitus (RR, 1.26; P  .009),
metabolic syndrome (RR, 1.25; P  .007), hemodialysis
status (RR, 1.91; P  .0002), critical ischemia at presenta-
tion (RR, 2.99; P  .001), recurrent occlusion (RR, 2.95;
P  .001), and poor tibial runoff (RR, 1.61; P  .003)
Fig 3. Life-table analysis of patients in the primary endo
from recurrent symptoms, (C) limb salvage, and (D) reta
mean (SEM) and number of limbs at risk is presented in
the data set terminates if the number at risk is 10.were the factors negatively affecting freedom from recur-rent symptoms and long-term clinical success after reinter-
vention.
DISCUSSION
The current study has demonstrated that repeat inter-
ventions for SFA disease are associated with similar short-
term and long-term anatomic and functional outcomes to
the primary endovascular intervention if there is no pro-
gression of disease. However, some of these patients do
present with disease progression and loss of runoff between
the primary and the repeat intervention; as a result, bypasses
were performed in patients with more advanced lesions and
poorer runoff. The anatomic outcomes for bypass were
superior to outcomes in the primary or the repeat endo
groups, despite the worsened anatomic classification and
runoff. Clinical outcomes did notmatch patency outcomes,
with no significant difference among the repeat endo and
bypass groups.
Patient survival during the study period was very good
in all groups and exceeded many previously published
reports.7,16,17 Our study found congestive heart failure and
at endo, and bypass groups for (A) survival, (B) freedom
linical success. Data are themean standard error of the
able. No error bars are shown if the SEM is 10%, and, repe
ined c
the themodialysis, both end-organ diseases, were negative prog-
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poor runoff, and major amputation, all surrogate markers
of advanced atherosclerosis, were also associated with in-
creased mortality. Statin administration did not influence
survival. A disappointing finding was that the penetration
of statin therapy was only 60% in the three cohorts and fell
below the national guidelines.18
Restenosis and reocclusion are common in lower ex-
tremity interventions. The failure rate through restenosis
and occlusion was 40%  3% at 5 years. There was no
significant difference in the groups with regard to age and
gender. Several risk factors, such as current smoking and
metabolic syndrome, were more prevalent in the bypass
group than in the repeat endo group. In addition, the
anatomic features of the lesion, according to TASC-II
category and runoff, were worse in the bypass group than in
the repeat endo group. The finding that runoff worsens
after intervention is not unique and was reported before by
McLafferty et al.19
We found that the presence of metabolic syndrome and
hemodialysis status, advanced lesions, poor runoff, and
presentation with critical ischemia were predictive factors
for failure. These factors have also been associated with
bypass failure and are consistent with those of other work
on SFA interventions.8,9,20-22 In the bypass group, patient
gender, age, indication for surgery, diabetes mellitus or
renal disease, and vein graft conduit type were not predic-
tive of the need for subsequent revision.20 Bypass grafts
that required revision because of early lesions (6 months
from index graft placement) were more likely to require an
additional revision procedure.20 We did find a similar rela-
tionship between early failure of SFA intervention and early
failure of the reintervention (endovascular or bypass).
Grey et al14 suggested that despite reintervention in
failed SFA intervention for long-segment disease, out-
comes were poor (46% at 1 year). In a small randomized
trial by van der Zaag et al,23 reocclusion occurred in more
than half of the patients randomized to percutaneous trans-
luminal angioplasty (PTA), with an absolute risk reduction
of 31% (95% confidence interval, 6%-56%) in favor of bypass
surgery. The hazard ratio for occlusion comparing PTA
with bypass surgery was 2.24 (95% confidence interval,
0.9-5.58).23 Ryer et al13 reported 45 patients with a failing
or failed endoluminal intervention, of which 4% failed in
the first 30 days, 78% failed between 1 and 18 months, and
18% failed after 18 months, with a mean time to failure of
8.7 months. Of these, 82% were candidates for a second
endovascular procedure, 11% were suitable for a traditional
open bypass, and 4% demonstrated progression of disease
necessitating amputation.
Multiple modalities are available to address restenosis
and occlusion after SFA intervention, including primary
thrombolysis with secondary intervention, repeat conven-
tional balloon or cutting-balloon angioplasty, stenting with
conventional and drug-eluting stents, and the use of
atherectomy devices to debulk the lesion.3,4 A pilot study
found cutting-balloon angioplasty failed to demonstratesuperiority over conventional balloon angioplasty for treat-
ment of femoropopliteal in-stent restenosis.24
Reports have demonstrated that early failure of endolu-
minal therapy for SFA disease is not associated with signif-
icant morbidity and mortality. Options for surgical bypass
are not compromised, and the amputation level is not
altered.12 However, early failure after isolated endovascular
intervention of the SFA alters the distal target in 30% of
early-failure patients if open bypass is planned.25 Bypass for
failed SFA stenting has been reported by Boeckler et al,26
and they demonstrated that these procedures are associated
with high complication rates and poor outcome, including
major amputations. Primary patency rates at 30 days and at
6 and 12 months were 67%, 44%, and 33%, respectively, in
the poststent bypass cohort vs 98%, 96%, and 88%, respec-
tively, in a contemporaneous group of patients treated with
primary bypass grafting.26 In our study, we found that early
failure (6 months) in the primary endo group was associ-
ated with early failure in the bypass group. The likely
effectors of this observation were presentation with critical
limb ischemia, worsened TASC-II lesion category, and
poorer runoff.
The goal of vascular interventions is to improve symp-
toms, prevent limb loss, and maintain or improve quality of
life. Karch et al27 showed that most clinical failures after
SFA intervention were due to anatomic failure, but a sig-
nificant number occurred despite patency at the site of the
SFA intervention. Although primary clinical success rates
were inferior to surgical bypass graft, supplemental PTA
was possible in 50% of patients.27
If a broader composite view of success encompassing
the absence of clinical symptoms, maintenance of ambula-
tion, and lack of a major amputation is used, only50% of
patients maintained a good outcome and it trended down-
ward after repeat endovascular intervention and bypass.
This correlated well with the findings that these groups
have more critical ischemia, worse TASC-II lesions, and
poor vessel tibial runoff. In bypass surgery, age, preopera-
tive ambulatory ability, independent living status, critical
limb ischemia, graft patency, and amputation predict am-
bulation 1 year,28 whereas dialysis, tissue loss, age 75
years, and coronary artery disease are good estimates of
amputation-free survival (the Edifoligide for the Preven-
tion of Infrainguinal Vein Graft Failure [PREVENT] III
Risk Score).29
In the current study, limb salvage was worse at 5 and
10 years with bypass than with endovascular interven-
tions, even though patency was better. Although major
amputation was not associated with graft occlusion, it
was associated with presenting symptoms (rest pain and
tissue loss) and poor runoff. Freedom from recurrent
symptoms (recurrence of the presenting complaint or
worse) is better, but this can be achieved with amputa-
tion and the patient falls out of the life table. This
difference highlights the need to adopt a composite
measure in reporting outcomes as it pertains to the effect
on the patient’s role in society.
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the limitations associated with such studies. This is a
report of clinical practice spanning 2 decades and there-
fore is at the mercy of changes in surgical practice,
anesthesia techniques, preoperative and postprocedural
risk factors reduction, and improvements in duplex im-
aging. Operator experience and technology changed
over time for both primary and repeat interventions, and
practice patterns advanced to where more advanced le-
sions were treated. It is highly likely that newer modali-
ties were used for secondary interventions because they
were more prevalent and accessible. The lack of random-
ization allowed individual physicians’ judgment to pre-
vail, and it appears that worsening lesion category and
worsening runoff prompted bypass surgery, indicating a
degree of bias that would have affected the outcomes.
Regardless of these weaknesses, this study does provide a
window on the outcomes of reintervention after SFA
interventions.
CONCLUSION
Reintervention is required in a minority of patients
selected for SFA angioplasty and is associated with similar
outcomes to the primary intervention. However, some of
these patients do show progression of their disease, and
bypass is more commonly used in these patients, with
superior long-term outcomes. Early primary failure 6
months is linked to subsequent early failure of a subsequent
bypass. This study suggests that bypass rather than repeat
PTA may be the better strategy for progressive and ad-
vanced recurrent SFA disease.
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of the manuscript.
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Methodology. For each patient captured, demo-
graphics, symptoms, existing comorbid conditions, and risk
factors for atherosclerosis were identified. Risk factors for
each patient were identified and corrected through his or
her primary care provider. Therapy for individual patients
was dictated by individual attending physician p reference
and was not regulated by unit guidelines. All patients
received aspirin daily (81 mg or 325 mg) as a general
cardiovascular protection agent.
Noninvasive studies were performed initially; however,
patients with serious symptoms or signs of severe stenosis or
occlusion based on the initial noninvasive tests received angio-
grams. Angiograms and angiographic reports were reviewed,
and lesions were described by length, calcification, and pa-
tency and then categorized under the TransAtlantic Inter-
Society Consensus (TASC) II system.1
Preoperative distal runoff was scored by the number of
patent tibial vessels and according to a modification of
Society for Vascular Surgery criteria for determining bypass
runoff that uses the cumulative score for the distal popliteal
from the knee joint to first tibial branch (max 9  1) and
each of the tibial vessels (max 3 each), giving a maximum
possible total score of 19.
Patients were taking aspirin preoperatively, and in the
last 5 years, patients also received clopidogrel preopera-
tively.
Angioplasty was performed under systemic heparin ad-
ministration (40 to 60 U/kg), and completion angiogra-
phy was performed to assess the technical result. Stents
were used at the discretion of the operator primarily or as an
adjunct for flow-limiting dissections, intimal flaps, or poor
technical results (50% residual stenosis). No covered
stents were used. No procedures or interventions were
performed that could have potentially jeopardized the out-
flow vessel for a bypass.
The complexity of each intervention was scored accord-
ing to the ad hoc system described by DeRubertis et al2 in
which one point was awarded for an intervention in the
iliac, femoral, or tibial segments of the leg.
Patients in whom the endoluminal intervention was
successful received clopidogrel (75 mg/d), and aspirin
therapy was maintained at 81 mg/d. Patients who were
already taking clopidogrel before the intervention contin-
ued taking it after the intervention. Clopidogrel therapy
was continued for 30 days after intervention.
Patients underwent routine duplex imaging follow-up
at 1, 3, and every 6 months using the criteria previously
described. During follow-up, angiography was only per-
formed if noninvasive studies suggested restenosis or occlu-
sion (positive duplex scan with a drop in the ankle-brachial
index of 0.15 and toe-brachial index of 0.1) and the
patient had recurrent symptoms.
Therapy for recurrent disease. The choice of inter-
vention was operator-dependent and there was no set pro-
tocol to manage reocclusion or stenosis during the study
period. In general, restenosis after primary angioplasty oratherectomy underwent repeat angioplasty or was primarily
stented. Recurrent in-stent restenosis was restented or un-
derwent atherectomy. Bypass surgery was most often used
for failed recannulization and long lesions. Endoscopic vein
harvest was performed when a satisfactory vein was avail-
able. If a prosthetic graft was chosen, polytetrafluoroethyl-
ene (6 or 8 mm) or Dacron (6 or 8 mm) was used.
Definitions. Coronary artery disease was defined as a
history of angina pectoris, myocardial infarction, conges-
tive heart disease, or prior coronary artery revasculariza-
tions. Cerebrovascular disease was defined as a history of
stroke, transient ischemic attack, or carotid artery revascu-
larization.
Chronic renal impairment was defined as an estimated
glomerular filtration rate 60 mL/min/1.73 m2 or if the
patient required dialysis. Hypertension was defined as a
systolic blood pressure  150 mm Hg or diastolic blood
pressure  90 mm Hg on three occasions during a
6-month period. Hypercholesterolemia was defined as fast-
ing serum concentrations of cholesterol 200 mg/dL, a
low-density lipoprotein 130 mg/dL, or triglycerides
200 mg/dL.
Diabetes was defined as a fasting plasma glucose 110
mg/dL or a hemoglobin A1c level 7%. Noninsulin-
dependent diabetes mellitus was defined as any patient with
diabetes mellitus who did not routinely receive insulin
therapy for diabetes management. Insulin-dependent dia-
betes mellitus was defined as any patient with diabetes
mellitus who routinely received insulin therapy. Metabolic
syndrome was defined as previously described3 (insulin
resistance or impaired glucose tolerance, hypertension, dys-
lipidemia, and abdominal obesity), with the exception of
abdominal circumference, which was not routinely re-
corded. We substituted a body mass index score 30.0
kg/m2 as a positive score instead of an abdominal circum-
ference 102 cm for men or 88 cm for women.
TASC-II classification of disease severity for femoral
lesions was used to define the categories of lesions.1
A death 30 days of the procedure was considered
procedurally related. A major complication was any event,
regardless of how minimal, not routinely observed after
endoluminal therapy that required treatment with a thera-
peutic intervention or rehospitalization 30 days of the
procedure. Systemic complications were those related to
cardiac, pulmonary, renal, and sepsis. Local complications
were those related to access site, surgical wounds, and the
treated limb. Symptoms before and after the procedure
were defined by Society for Vascular Surgery (SVS) crite-
ria,4 and a drop in symptom score of 1 in follow-up was
considered as recurrent symptoms.
Lesion restenosis was classified on the basis of length of
restenosis in relation to stented length. Four categories of
in-stent restenosis were defined: (I) focal (10 mm
length), (II) diffuse (10 mm length), (III) proliferative
(10 mm length and extending outside the stent), and
(IV) occlusion.
Primary, assisted primary, and secondary patency rates
were defined in accordance with the reporting standards of
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the following occurred: absence of recurrent symptoms for
1 year, patency of the intervention until wound healing,
limb salvage for 1 year, maintenance of ambulation for 1
year, and survival for 1 year. Freedom from target lesion
revascularization was defined as the absence of clinically
driven repeat revascularization of the target lesion (endo-
vascular therapy for symptomatic stenosis or occlusion) or
the need for surgical bypass grafting or amputation due to
reocclusion of the target lesion as diagnosed by arteriogra-
phy or duplex scan. Retained clinical success was defined as
absence of recurrent symptoms, maintenance of ambula-
tion, and limb preservation.
Statistical analysis. All statistical analyses were per-
formed on an intention-to-treat basis. Measured values are
reported as percentages or means  standard deviation.
Patency and limb salvage rates are calculated using Kaplan-
Meier analysis and reported using current SVS criteria.4Standard errors are reported in Kaplan-Meier analyses. Cox
proportional hazard analyses and univariate and multivari-
ate analyses were performed to identify factors associated
with outcomes. Analyses were performed using JMP 7.0
software (SAS Institute, Cary, NC).
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